• Published in Inflammatory Bowel Diseases (2024)

  • Collaborator: Takeda Pharmaceuticals International AG

  • Authors: Gionata Fiorino, Nawal Bent-Ennakhil, Pasquale Varriale, Fiona Braegger, Eveline Hoefkens

This study explored patients’ preferences for treatment attributes in Crohn’s disease or ulcerative colitis, such as subcutaneous/intravenous drug administration and adverse effects. Patients’ preferences highlighted the importance of personalized care and shared decision making to maximize treatment benefits.